ライフサイエンスコーパス: adrenal tumor

1 luded a CT scan, which now visualized a left adrenal tumor.

2 to LTLA in the treatment of small and benign adrenal tumors.

3 en operating on pheochromocytomas and larger adrenal tumors.

4 method for treating small functional primary adrenal tumors.

5 he procedure for the most challenging of the adrenal tumors.

6 higher risk for diabetes than those without adrenal tumors.

7 like growth factor II, have been reported in adrenal tumors.

8 ding the optimal evaluation and treatment of adrenal tumors.

9 ometabolic outcomes compared with absence of adrenal tumors.

10 ypercortisolism or in 82 patients with other adrenal tumors.

11 omen, seven men; mean age, 63 years) with 23 adrenal tumors (16 adenomas, six metastases, one adrenoc

12 cident composite diabetes than those without adrenal tumors (30 of 110 [27.3%] vs. 72 of 615 [11.7%]

13 Of 64 adrenal tumors, 55 were initially considered benign, 6 h

14 Perhaps most significantly, MEN2A adrenal tumors also display these changes in cell cycle

15 r in childhood/adolescence had primary extra-adrenal tumors and harbored SDHB mutations.

16 terization studies, are useful in localizing adrenal tumors and in distinguishing between benign and

17 the preferred technique for removing benign adrenal tumors and isolated metastases.

18 mice bearing either s.c. or orthotopic intra-adrenal tumors, and 40% of mice bearing induced metastat

19 Background: Benign adrenal tumors are commonly discovered on abdominal imag

20 Most primary adrenal tumors are sporadic, but may be associated with

21 Adrenal tumors are very common, with the majority being

22 ment of whether the classification of benign adrenal tumors as "nonfunctional" adequately reflects th

23 Adrenal tumors autonomously producing cortisol cause Cus

24 choice for functional and primary malignant adrenal tumors, both for cure and palliation, with low m

25 NH(-/-)-LH-CTP mice not only fail to develop adrenal tumors but have smaller adrenals, with a regress

26 but exhibited residual toxicity on mouse Y-1 adrenal tumor cells and had an ability equivalent to tha

27 aberrant expression of ectopic receptors on adrenal tumor cells have been implicated in adrenal cell

28 galactose and to GM1, toxicity on mouse Y-1 adrenal tumor cells, the ability to stimulate adenylate

29 Adrenal tumors evoke considerable interest and diagnosti

30 vated LH levels are not sufficient to induce adrenal tumor formation.

31 Evaluation of adrenal tumors from 118 adult patients demonstrated an i

32 nd treatment approaches in the management of adrenal tumors; further research is necessary.

33 upports the conclusion that activin inhibits adrenal tumor growth by inducing x-zone regression.

34 New adrenal tumors have also been associated with nonheredit

35 ional imaging is recommended to characterize adrenal tumors; however, mistakes may occur and therefor

36 mon presentation was that of a single benign adrenal tumor in patients older than 40 years.

37 All mutation carriers had adrenal tumors, including 7 bilateral (P = 2.7 x 10(-4))

38 concentration; this patient had a very small adrenal tumor (<1 cm).

39 o evaluate the hypothesis that nonfunctional adrenal tumors (NFATs) increase risk for cardiometabolic

40 Extra-adrenal tumors occurred in 28 mutation carriers (48%) an

41 nes, and all had radiographic evidence of an adrenal tumor or tumors.

42 functional variants previously implicated in adrenal tumor predisposition, and one (Y727C) was a know

43 sterase 11A (PDE11A) have been implicated in adrenal tumor susceptibility.

44 TP mice develop large, sex steroid-producing adrenal tumors that arise from the x zone, indicating a

45 sistent with Li-Fraumeni syndrome-associated adrenal tumors, there was no history of increased cancer

46 n several familial syndromes associated with adrenal tumors; these include menin, which is responsibl

47 enalectomy the method of choice for removing adrenal tumors; this type of surgery allows shorter hosp

48 NFATs ("exposed"; n = 166) and those with no adrenal tumor ("unexposed"; n = 740), with at least 3 ye

49 ients (undergoing 13 procedures) with single adrenal tumors were included in the analysis.

50 ncreases with age, appropriate management of adrenal tumors will be a growing challenge in our aging

51 t reliable parameter for characterization of adrenal tumors with 3.0-T MR imaging when obtaining OP e